Melanotan II
Melanotan II is a synthetic cyclic peptide that acts as a non-selective agonist at melanocortin receptors, developed as an analogue of the naturally occurring hormone alpha-melanocyte-stimulating hormone (alpha-MSH). It has been studied primarily for its ability to stimulate skin pigmentation, and it also produces effects on appetite and sexual arousal through its action on central melanocortin pathways. Despite its widespread gray-market availability, Melanotan II is not an approved or licensed drug in any major jurisdiction. A related derivative, bremelanotide (PT-141), was developed to focus more selectively on the MC4R pathway for sexual function.
Side effects & risks
Melanotan II is associated with a substantial and well-documented set of adverse effects, and safety concerns should be weighed carefully before the anecdotal effects. The most commonly reported short-term effects are nausea (sometimes with vomiting), facial flushing, spontaneous erections, decreased appetite, and darkening of existing skin. A specific and serious dermatological concern is that the compound darkens existing moles and can drive the appearance of new or atypical melanocytic nevi; multiple case reports have described changing pigmented lesions in users, and cases have raised concern about melanoma, making the melanoma question an unresolved and important safety signal rather than a settled one. Priapism (a prolonged, painful erection) is a recognized risk and can constitute a medical emergency requiring urgent care. Effects on blood pressure and cardiovascular parameters have also been reported. Because gray-market products are unregulated, there are additional risks of contamination, incorrect dosing, and unsterile injection practices. Melanotan II is not appropriate for people with a personal or family history of melanoma or numerous or atypical moles, and it should not be used without medical oversight. Anyone considering or using it should have baseline and ongoing dermatological monitoring of their skin and moles by a qualified clinician, and any changing lesion should prompt prompt evaluation.
Latest studies
Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use.
A case report describes a patient who developed five early-stage melanomas after recent tanning bed use, melanotan exposure, and anabolic hormone use.
Unregulated Melanotan Use Promoted via Social Media: Emerging Dermatologic and Public Health Risks.
A commentary highlights the dermatologic and public-health risks of unregulated melanotan use being promoted through social media.
Depigmented Facial and Neck Patches Following Melanotan Use in a Patient With Atopic Dermatitis and Alopecia Areata.
A case report describes depigmented patches on the face and neck following melanotan use in a patient who also had atopic dermatitis and alopecia areata.
Reported protocols (with caveats)
Melanotan II is described in research and community contexts as a research-use-only compound, not an approved therapy, and any use falls outside regulatory approval. Reported community practice typically distinguishes a loading phase, in which smaller doses are administered daily to build up pigmentation, from a lower-frequency maintenance phase intended to sustain it. The reported route is almost always subcutaneous injection, and reported doses are commonly titrated upward gradually to gauge individual tolerance to nausea and flushing. Some community reports pair use with controlled ultraviolet exposure to develop pigment, while others describe on-demand use for its reported effects on sexual arousal. These patterns reflect anecdotal convention rather than any established or recommended dosing standard, and no regulatory or clinical body endorses them. Because gray-market products vary in concentration and purity, reported doses cannot be assumed to correspond to the actual amount delivered.